RU2212899C2 - Hcv иммунореактивные полипептидные композиции - Google Patents
Hcv иммунореактивные полипептидные композицииInfo
- Publication number
- RU2212899C2 RU2212899C2 RU98117084/14A RU98117084A RU2212899C2 RU 2212899 C2 RU2212899 C2 RU 2212899C2 RU 98117084/14 A RU98117084/14 A RU 98117084/14A RU 98117084 A RU98117084 A RU 98117084A RU 2212899 C2 RU2212899 C2 RU 2212899C2
- Authority
- RU
- Russia
- Prior art keywords
- hcv
- polypeptide
- amino acid
- envelope
- variable domain
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract 23
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 23
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 23
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 6
- 102000039446 nucleic acids Human genes 0.000 claims abstract 6
- 108020004707 nucleic acids Proteins 0.000 claims abstract 6
- 241000711549 Hepacivirus C Species 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108700008783 Hepatitis C virus E1 Proteins 0.000 claims 6
- 108010076039 Polyproteins Proteins 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000037029 cross reaction Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
Abstract
Изобретение относится к медицине и касается НСV иммунореактивных полипептидных композиций. Сущность изобретения включает молекулы нуклеиновой кислоты, кодирующие иммунореактивные полипептиды, содержащие вирусные эпитопы гепатита типа С. Преимущество изобретения заключается в создании полипептидных композиций, которые иммунологически перекрестно-реактивны с многими изолятами HCV, особенно относительно гетерогенных доменов вируса. 3 с. и 2 з. п. ф-лы, 6 табл., 9 ил.
Description
Текст описания в факсимильном виде (см. графическую часть)о
Claims (5)
1. Молекула нуклеиновой кислоты, кодирующая иммунореактивный оболочечный полипептид вируса гепатита С (НСV), отличающаяся тем, что указанный полипептид содержит, по крайней мере, две гетерогенные аминокислотные последовательности, происходящие из разных изолятов НСV, причем каждая последовательность включает по крайней мере один эпитоп из (i) вариабельного домена оболочечного полипептида Е2/NS1 HCV, причем указанный вариабельный домен оболочечного полипептида Е2/NS 1 имеет аминокислотную последовательность 384-414 полипротеина HCV, используя систему нумерации аминокислот HCV-1 и/или (ii) вариабельного домена оболочечного полипептида Е1 HCV, причем указанный вариабельный домен оболочечного полипептида Е1 HCV имеет аминокислотную последовательность 215-255 полипротеина HCV, используя систему нумерации аминокислот HCV-1.
2. Молекула нуклеиновой кислоты, кодирующая иммунореактивный оболочечный полипептид вируса гепатита С (HCV), отличающаяся тем, что указанный полипептид содержит, по крайней мере, две гетерогенные аминокислотные последовательности, происходящие из разных изолятов HCV, причем каждая последовательность включает (i) эпитоп, который происходит из вариабельного домена оболочечного полипептида Е1 HCV, причем указанный вариабельный домен полипептида E1 HCV имеет аминокислотную последовательность 215-255 полипротеина HCV, используя систему нумерации аминокислот HCV-1, и (ii) дополнительный второй эпитоп, происходящий из вариабельного домена оболочечного полипептида Е2/NS1 HCV, причем указанный вариабельный домен оболочечного полипептида Е2/NS1 HCV имеет аминокислотную последовательность 384-414 HCV полипротеина, используя систему нумерации аминокислот HCV-1.
3. Молекула нуклеиновой кислоты по п. 1 или 2, отличающаяся тем, что различные HCV изоляты включают изоляты HCV группы I и изоляты HCV группы II.
4. Набор молекул нуклеиновых кислот, кодирующих наборы антигенов HCV, представляющих собой иммунореактивные оболочечные полипептиды, отличающийся тем, что каждый набор HCV антигенов состоит из множества фактически идентичных аминокислотных последовательностей, происходящих из различных изолятов HCV, содержащих, по крайней мере, один эпитоп из (i) вариабельного домена оболочечного полипептида Е2/NS1 HCV, причем указанный вариабельный домен оболочечного полипептида Е2/NS1 HCV имеет аминокислотную последовательность 384-414 полипротеина HCV, используя систему нумерации аминокислот HCV-1, и/или (ii) вариабельного домена оболочечного полипептида Е1 HCV, причем указанный вариабельный домен оболочечного полипептида Е1 HCV имеет аминокислотную последовательность 215-255 HCV полипротеина, используя систему нумерации аминокислот HCV-1, и, где фактически идентичные аминокислотные последовательности из данного набора включают, по крайней мере, один эпитоп, гетерогенный относительно последовательности эпитопа, по крайней мере, одного, другого набора.
5. Набор молекул нуклеиновых кислот по п. 4, отличающийся тем, что различные HCV изоляты включают изоляты группы I и изоляты группы II.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75957591A | 1991-09-13 | 1991-09-13 | |
US759,575 | 1991-09-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU98117084A RU98117084A (ru) | 2000-06-27 |
RU2212899C2 true RU2212899C2 (ru) | 2003-09-27 |
Family
ID=25056174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98117084/14A RU2212899C2 (ru) | 1991-09-13 | 1992-09-11 | Hcv иммунореактивные полипептидные композиции |
RU94024561A RU2136311C1 (ru) | 1991-09-13 | 1992-09-11 | Иммуногенная полипептидная композиция, способ получения композиции, способ продуцирования и способ обнаружения антител, набор |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94024561A RU2136311C1 (ru) | 1991-09-13 | 1992-09-11 | Иммуногенная полипептидная композиция, способ получения композиции, способ продуцирования и способ обнаружения антител, набор |
Country Status (16)
Country | Link |
---|---|
US (6) | US5756312A (ru) |
EP (1) | EP0608261B1 (ru) |
JP (5) | JPH06511149A (ru) |
AT (1) | ATE228564T1 (ru) |
AU (1) | AU679429B2 (ru) |
BG (1) | BG62973B1 (ru) |
CA (1) | CA2116764C (ru) |
DE (1) | DE69232859T2 (ru) |
DK (1) | DK0608261T3 (ru) |
ES (1) | ES2182822T3 (ru) |
FI (1) | FI112438B (ru) |
HU (1) | HU227510B1 (ru) |
PL (2) | PL171972B1 (ru) |
RO (1) | RO116199B1 (ru) |
RU (2) | RU2212899C2 (ru) |
WO (1) | WO1993006126A1 (ru) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596476B1 (en) * | 1989-12-22 | 2003-07-22 | Abbott Laboratories | Hepatitis C assay |
JPH06511149A (ja) * | 1991-09-13 | 1994-12-15 | カイロン コーポレイション | 免疫反応性c型肝炎ウイルスのポリペプチド組成物 |
US6297048B1 (en) * | 1992-02-04 | 2001-10-02 | Chiron Corporation | Hepatitis therapeutics |
US6667387B1 (en) | 1996-09-30 | 2003-12-23 | N.V. Innogenetics S.A. | HCV core peptides |
US6709828B1 (en) | 1992-03-06 | 2004-03-23 | N.V. Innogenetics S.A. | Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them |
DE69332485T2 (de) * | 1992-08-11 | 2003-11-13 | Harvard College | Immunmodulierende peptide |
US6762024B2 (en) * | 1993-04-27 | 2004-07-13 | Innogenetics, S.A. | Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents |
US7255997B1 (en) | 1993-04-27 | 2007-08-14 | N.V. Innogenetics S.A. | Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents |
EP0697888B1 (en) | 1993-05-12 | 2003-09-17 | Chiron Corporation | Conserved motif of hepatitis c virus e2/ns1 region |
US5514539A (en) * | 1993-06-29 | 1996-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
DK0725824T3 (da) | 1993-11-04 | 2003-08-11 | Innogenetics Nv | Immunodominante humane T-celleepitoper af hepatitis C virus |
DE59511054D1 (de) | 1994-07-25 | 2006-08-10 | Roche Diagnostics Gmbh | Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene |
US6150134A (en) | 1994-07-29 | 2000-11-21 | Innogenetics, N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
EP1076092A3 (en) | 1994-10-21 | 2001-03-28 | Innogenetics N.V. | Sequences of hepatitis C virus type10 and their use as prophylactic, therapeutic and diagnostic agents |
US6110465A (en) * | 1995-06-07 | 2000-08-29 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines |
US6127116A (en) * | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
US7235394B1 (en) | 1995-08-29 | 2007-06-26 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
US7045363B2 (en) * | 1996-05-01 | 2006-05-16 | Fujirebio Inc. | Nucleic acid-bound polypeptide method of producing nucleic acid-bound polypeptide and immunoassay using the polypeptide |
US6001613A (en) * | 1996-05-24 | 1999-12-14 | Board Of Regents Of University Of Nebraska | Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid |
WO1998021338A1 (en) | 1996-11-08 | 1998-05-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Synthesis and purification of hepatitis c virus-like particles |
US6322965B1 (en) * | 1997-02-10 | 2001-11-27 | Advanced Life Science Institute, Inc. | Chimera antigen peptide |
US7338759B1 (en) | 1997-03-04 | 2008-03-04 | Washington University | HCV variants |
US7049428B1 (en) * | 1998-03-04 | 2006-05-23 | Washington University | HCV variants |
AU752131C (en) * | 1997-11-06 | 2003-12-04 | Innogenetics N.V. | Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes |
US7157435B2 (en) | 1998-04-15 | 2007-01-02 | The Regents Of The University Of California | Methods for modulation of the effects of aging on the primate brain |
US6815431B2 (en) | 1998-04-15 | 2004-11-09 | Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
US6683058B1 (en) | 1998-04-15 | 2004-01-27 | Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
US6451306B1 (en) | 1998-04-15 | 2002-09-17 | The Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
US7052830B1 (en) | 1998-06-09 | 2006-05-30 | Branch Andrea D | Hepatitis C virus peptides and uses thereof |
US7108855B2 (en) * | 1998-06-24 | 2006-09-19 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
US6548634B1 (en) * | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
US7091324B2 (en) | 1998-11-05 | 2006-08-15 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
US20030180284A1 (en) * | 1998-11-05 | 2003-09-25 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes |
US6689879B2 (en) | 1998-12-31 | 2004-02-10 | Chiron Corporation | Modified HIV Env polypeptides |
EP1141313A2 (en) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
WO2000039304A2 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
EP1535628B1 (en) * | 1999-11-24 | 2013-07-31 | Novartis Vaccines and Diagnostics, Inc. | Hbv/hcv virus-like particle |
US6740323B1 (en) | 1999-11-24 | 2004-05-25 | Chiron Corporation | HBV/HCV virus-like particle |
IL153831A0 (en) * | 2000-07-19 | 2003-07-31 | Univ California | Methods for therapy of neurodegenerative disease of the brain |
US6858590B2 (en) * | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
CA2419418A1 (en) | 2000-08-17 | 2002-02-21 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US6680059B2 (en) * | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US6682909B2 (en) | 2000-09-13 | 2004-01-27 | Hawaii Biotech, Inc. | Immunogenic composition of hepatitis C and methods of use thereof |
JP5033303B2 (ja) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
JP4302513B2 (ja) * | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗原性b型hivポリペプチドおよび/または抗原性c型hivポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用 |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
CA2458995C (en) * | 2001-08-31 | 2013-04-30 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
AR045702A1 (es) * | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
WO2005007808A2 (en) | 2003-05-15 | 2005-01-27 | Chiron Corporation | Hiv polynucleotides and polypeptides derived from botswana mj4 |
US20050202036A1 (en) * | 2003-07-22 | 2005-09-15 | Branch Andrea D. | Alternate reading frame polypeptides drived from hepatitis C and methods of their use |
WO2005017125A2 (en) * | 2003-08-14 | 2005-02-24 | California Institute Of Molecular Medicine | Method for isolation and replication of infectious human hepatitis-c virus |
US8124747B2 (en) | 2003-08-29 | 2012-02-28 | Innogenetics | HCV clade and prototype sequences thereof |
WO2006050394A2 (en) | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
WO2007031867A2 (en) * | 2005-05-25 | 2007-03-22 | Tripep Ab | A hepatitis c virus non-stru tural ns3/4a fusion gene |
AU2007207544A1 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
US8071561B2 (en) * | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
US20100286070A1 (en) * | 2007-09-14 | 2010-11-11 | Gert Verheyden | Affinity tag |
SG185263A1 (en) | 2007-09-28 | 2012-11-29 | Portola Pharm Inc | Antidotes for factor xa inhibitors and methods of using the same |
WO2009130588A2 (en) * | 2008-04-22 | 2009-10-29 | Tripep Ab | Immunogen platform |
US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
WO2010117729A1 (en) | 2009-03-30 | 2010-10-14 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
WO2010148117A1 (en) | 2009-06-17 | 2010-12-23 | Scantibodies Laboratory, Inc. | Therapeutic and diagnostic affinity purified specific polyclonal antibodies |
EP2453910B1 (en) | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
EP3424495A1 (en) | 2011-07-06 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
JP6120839B2 (ja) | 2011-07-06 | 2017-04-26 | ノバルティス アーゲー | カチオン性水中油型エマルジョン |
US8609355B2 (en) | 2011-07-26 | 2013-12-17 | Indicator Systems International, Inc. | Assays for the detection of microbes |
FR2984328B1 (fr) | 2011-12-20 | 2016-12-30 | Bio-Rad Innovations | Procede de detection d'une infection par le virus de l'hepatite c |
AU2013234046B2 (en) | 2012-03-16 | 2017-09-07 | University Health Network | Methods and compositions for modulating Toso activity |
RU2520710C1 (ru) * | 2012-12-10 | 2014-06-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО ЧелГМА Минздравсоцразвития России) | Способ прогнозирования персистенции онкогенных типов вируса папилломы человека в цервикальном эпителии |
CA2941697A1 (en) | 2014-03-07 | 2015-09-11 | University Health Network | Methods and compositions for modifying the immune response |
RU2675108C2 (ru) * | 2015-06-15 | 2018-12-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) | Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с |
US10287338B2 (en) | 2015-07-10 | 2019-05-14 | Miran NERSISSIAN | Factor VIII protein compositions and methods of treating of hemophilia A |
EP3365027B1 (en) | 2015-10-14 | 2022-03-30 | Research Institute at Nationwide Children's Hospital | Hu specific antibodies and their use in inhibiting biofilm |
US11564982B2 (en) | 2017-01-04 | 2023-01-31 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
WO2018129092A1 (en) | 2017-01-04 | 2018-07-12 | Research Institute At Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
WO2018170178A1 (en) | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
US20220275064A1 (en) | 2019-07-08 | 2022-09-01 | Research Institute At Nationwide Children's Hospital | Antibody compositions for disrupting biofilms |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3400079A1 (de) * | 1984-01-03 | 1985-07-11 | Röhm GmbH, 6100 Darmstadt | Wasserspreitendes kunststoffmaterial, verfahren zu seiner herstellung u. verwendung als verglasungs- und bedachungsmaterial |
NZ219516A (en) * | 1987-02-10 | 1991-02-26 | Wellcome Found | Fusion proteins of hbcag (hepatitis b virus core antigen) |
US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
CN1074422C (zh) * | 1987-11-18 | 2001-11-07 | 希龙股份有限公司 | 制备含有hcv表位的分离多肽的方法 |
HU225068B1 (en) * | 1989-03-17 | 2006-05-29 | Chiron Corp | Process for producing diagnostics and vaccine of nanbh |
MC2188A1 (fr) * | 1989-05-18 | 1992-09-16 | Chiron Corp | Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c |
US5372928A (en) * | 1989-09-15 | 1994-12-13 | Chiron Corporation | Hepatitis C virus isolates |
CA2065287C (en) * | 1989-09-15 | 1999-12-21 | Tatsuo Miyamura | New hcv isolates |
DE59109221D1 (de) * | 1990-11-03 | 2001-11-15 | Dade Behring Marburg Gmbh | HCV-spezifische Peptide, Mittel dazu und ihre Verwendung |
JPH06511149A (ja) * | 1991-09-13 | 1994-12-15 | カイロン コーポレイション | 免疫反応性c型肝炎ウイルスのポリペプチド組成物 |
-
1992
- 1992-09-11 JP JP5506119A patent/JPH06511149A/ja not_active Withdrawn
- 1992-09-11 ES ES92919917T patent/ES2182822T3/es not_active Expired - Lifetime
- 1992-09-11 DE DE69232859T patent/DE69232859T2/de not_active Expired - Lifetime
- 1992-09-11 CA CA002116764A patent/CA2116764C/en not_active Expired - Lifetime
- 1992-09-11 RU RU98117084/14A patent/RU2212899C2/ru active
- 1992-09-11 RO RO94-00391A patent/RO116199B1/ro unknown
- 1992-09-11 HU HU9400741A patent/HU227510B1/hu unknown
- 1992-09-11 WO PCT/US1992/007683 patent/WO1993006126A1/en active IP Right Grant
- 1992-09-11 RU RU94024561A patent/RU2136311C1/ru active
- 1992-09-11 EP EP92919917A patent/EP0608261B1/en not_active Expired - Lifetime
- 1992-09-11 PL PL92313797A patent/PL171972B1/pl unknown
- 1992-09-11 AU AU26436/92A patent/AU679429B2/en not_active Expired
- 1992-09-11 AT AT92919917T patent/ATE228564T1/de active
- 1992-09-11 DK DK92919917T patent/DK0608261T3/da active
- 1992-09-11 PL PL92302729A patent/PL171489B1/pl unknown
-
1994
- 1994-03-11 BG BG98653A patent/BG62973B1/bg unknown
- 1994-03-14 FI FI941199A patent/FI112438B/fi not_active IP Right Cessation
- 1994-04-19 US US08/231,368 patent/US5756312A/en not_active Expired - Lifetime
-
1995
- 1995-05-12 US US08/440,210 patent/US5766845A/en not_active Expired - Lifetime
- 1995-05-12 US US08/440,542 patent/US5670153A/en not_active Expired - Lifetime
- 1995-05-12 US US08/440,103 patent/US5670152A/en not_active Expired - Lifetime
- 1995-06-06 US US08/471,498 patent/US5728520A/en not_active Expired - Lifetime
-
1998
- 1998-03-24 US US09/046,604 patent/US6303292B1/en not_active Expired - Fee Related
-
2001
- 2001-07-11 JP JP2001211447A patent/JP2002167336A/ja not_active Withdrawn
-
2003
- 2003-09-18 JP JP2003326811A patent/JP2004073207A/ja not_active Withdrawn
-
2005
- 2005-01-27 JP JP2005020454A patent/JP4353905B2/ja not_active Expired - Lifetime
-
2008
- 2008-02-20 JP JP2008038799A patent/JP2008133301A/ja not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
OKAMOTO H. et al., Enzyme-Linked immunosorbent assay for antibodies against the capsid protein of hepatitis C virus with a synthetic oligopeptide. Japan. J. Exp. Med., 1990, v. 60, №4, рр. 223-233. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2212899C2 (ru) | Hcv иммунореактивные полипептидные композиции | |
RU98117084A (ru) | Hcv иммунореактивные полипептидные композиции | |
ATE195953T1 (de) | Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c | |
HU9303703D0 (en) | Hepatitis c virus (hcv) polypeptides | |
DK0754704T3 (da) | Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus | |
DK0992580T3 (da) | Epitoper på human T-celler, som er immundominante for hepatitis C-virus | |
WO1992017493A3 (en) | Peptides and mixtures thereof for detecting antibodies to hepatitis c virus (hcv) | |
KR870010196A (ko) | 프리(pre)-S 유전자 코우드된 펩티드, B형 간염면역 원, 왁찐, 진단법 및 합성지질소낭 담체 | |
DE69132365T2 (de) | Für den Nachweis von Antikörpern gegen HVC spezifische synthetische Peptide und Diagnose von HCV-Infektionen | |
SE9004010D0 (sv) | Viralt medel | |
NO863803L (no) | Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids). | |
DE60125751D1 (de) | Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1 | |
KR940703851A (ko) | E형 간염 바이러스 펩타이드 항원 및 항체(hepatitis e virus peptide antigens and antibodies) | |
DE69435059D1 (de) | Immunoreaktive antigene des hepatitis e viruses | |
WO1995032290A3 (en) | Non-a/non-b/non-c/non-d/non-e hepatitis agents and molecular cloning thereof | |
WO1993017110A3 (en) | A recombinant hepatitis c virus polypeptide | |
KR910016347A (ko) | C형 간염 바이러스에 대한 초면역 글로블린 및 이의 제조방법 | |
DE69008701T2 (de) | Ein b-epitop des hüllglykoproteins eines retrovirus und ein t-epitop eines anderen proteins dieses retrovirus enthaltende zusammensetzung. | |
DE494825T1 (de) | Synthetische peptide von hepatitis-b-virus-hbc-antigen. | |
Wang | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines | |
SG145521A1 (en) | Synthetic antigens for the detection of antibodies to hepatitis c virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner |